other material
confidence high
sentiment negative
materiality 0.65
Skye Bioscience transfers Nasdaq listing to Capital Market after equity deficiency; bid price non-compliance continues
Skye Bioscience, Inc.
- Nasdaq approved transfer from Global to Capital Market effective June 23, 2026 due to stockholders' equity of $9.0M below $10M requirement.
- Company previously disclosed bid price below $1 for 30 consecutive days; compliance period runs to Sept 14, 2026.
- Ticker symbol remains SKYE; transfer to Capital Market allows lower $3M equity standard.
- Company monitoring bid price and considering options but no assurance of regaining compliance.